APA (7th ed.) Citation

Packer, M., Butler, J., Filippatos, G. S., Jamal, W., Salsali, A., Schnee, J., . . . Jian, Z. (2019). Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: Rationale for and design of the EMPEROR‐Reduced trial. European Journal of Heart Failure, 21(10), 1270. https://doi.org/10.1002/ejhf.1536

Chicago Style (17th ed.) Citation

Packer, Milton, et al. "Evaluation of the Effect of Sodium–glucose Co‐transporter 2 Inhibition with Empagliflozin on Morbidity and Mortality of Patients with Chronic Heart Failure and a Reduced Ejection Fraction: Rationale for and Design of the EMPEROR‐Reduced Trial." European Journal of Heart Failure 21, no. 10 (2019): 1270. https://doi.org/10.1002/ejhf.1536.

MLA (9th ed.) Citation

Packer, Milton, et al. "Evaluation of the Effect of Sodium–glucose Co‐transporter 2 Inhibition with Empagliflozin on Morbidity and Mortality of Patients with Chronic Heart Failure and a Reduced Ejection Fraction: Rationale for and Design of the EMPEROR‐Reduced Trial." European Journal of Heart Failure, vol. 21, no. 10, 2019, p. 1270, https://doi.org/10.1002/ejhf.1536.